Synthesis and anticancer activity of glucosylated podophyllotoxin derivatives linked via 4β-triazole rings

Molecules

Volumn 18, Issue 11, 2013, Pages 13992-14012

  Zi, Cheng Ting ^a,b   Xu, Feng Qing ^a   Li, Gen Tao ^a   Li, Yan ^a   Ding, Zhong Tao ^b   Zhou, Jun ^a   Jiang, Zi Hua ^c   Hu, Jiang Miao ^a  

^a KUNMING INSTITUTE OF BOTANY   (China)

^b YUNNAN UNIVERSITY   (China)

^c LAKEHEAD UNIVERSITY   (Canada)

Author keywords

4 triazole ring; Anticancer activity; Click chemistry; Podophyllotoxin

Indexed keywords

ANTINEOPLASTIC AGENT; PODOPHYLLOTOXIN; TRIAZOLE DERIVATIVE;

ARTICLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MOLECULAR STRUCTURE; PODOPHYLLOTOXIN; TRIAZOLES;

EID: 84888592834     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules181113992     Document Type: Article

References (41)

1. Kelly, M.G.; Hartwell, J.L. The biological effects and the chemical composition of podophyllin: A review. J. Natl. Cancer Inst. 1954, 14, 967-1010.
2. Imbert, T.F. Discovery of podophyllotoxins. Biochimie 1998, 80, 207-222.
3. Jardine, I. Podophyllotoxins. In Anticancer Agents based on Natural Product Models; Cassady, J.M., Douros, J.D., Eds.; Academic Press: New York, NY, USA, 1980; pp. 319-351.
4. Gordaliza, M.; García, P.A.; Miguel del Corral, J.M.; Castro, M.A.; Gómez-Zurita, M.A. Podophyllotoxin: Distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004, 44, 441-459.
5. Xu, H.; Lv, M.; Tian, X. A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Curr. Med. Chem. 2009, 23, 327-349.
6. Lv, M.; Xu, H. Recent advances in semisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: An update (2008-2010). Mini Rev. Med. Chem. 2011, 11, 901-909.
7. Castro, M.A.; Miguel del Corral, J.M.; García, P.A.; Rojo, M.V.; de la Iglesia-Vicente, J.; Mollinedo, F.; Cuevas, C.; San Feliciano, A. Synthesis and biological evaluation of new podophyllic aldehyde derivatives with cytotoxic and apoptosis-inducing activities. J. Med. Chem. 2010, 53, 983-993.
8. Lee, K.H.; Imakura, Y.; Haruna, M.; Beers, S.A.; Thurston, L.S.; Dai, H.J.; Chen, C.H.; Liu, S.Y.; Cheng, Y.C. Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J. Nat. Prod. 1989, 52, 606-613.
9. Zhou, X.M.; Wang, Z.Q.; Chang, J.Y.; Chen, H.X.; Cheng, Y.C.; Lee, K.H. Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4'-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. J. Med. Chem. 1991, 34, 3346-3350.
10. Doyle, T.W. Etoposide VP-16 Current Status and New Developments; Academic Press: New York, NY, USA, 1984; p.19
11. Stahelin, H. 4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. Eur. J. Cancer 1970, 6, 303-311.
12. Terada, T.; Fujimoto, K.; Nomura, M.; Yamashita, J.; Wierzba, K.; Yamazaki, R.; Shibata, J.; Sugimoto, Y.; Yamada, Y. Synthesis and biological activity of 4β-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-O-demethyl-4-desoxypodophyllotoxin as antitumor agents. J. Med. Chem. 1993, 36, 1689-1699.
13. Xiao, Z.Y.; Xiao, Y.D.; Feng, J.; Golbraikh, A.; Tropsha, A.; Lee, K.H. Antitumor agents. 213. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR method. J. Med. Chem. 2002, 45, 2294-2309.
14. Tawa, R.; Takami, M.; Imakura, Y.; Lee, K.H.; Sakurai, H. Effects of CpG methylation to double stranded DNA breaks by Cu(II)-podophyllotoxin derivative complexes. Bioorg. Med. Chem. Lett. 1997, 7, 489-494.
15. Passarella D.; Peretto B.; Blasco, Y.; Yepes, R.; Cappelletti, G.; Cartelli, D.; Ronchi, C.; Snaith, J.; Fontana, G.; Danieli, B.; et al. Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates. Eur. J. Med. Chem. 2010, 45, 219-226.
16. Chen, S.W.; Xiangm, R.; Liu, J.; Tian, X. Synthesis and biological evaluation of novel conjugates of podophyllotoxin and 5-FU as antineoplastic agents. Bioorg. Med. Chem. 2009, 17, 3111-3117.
17. Sackett, D.L. Podophyllotoxin, suteganacin and combretastatin: Natural products that bind at the colchicine site of tubulin. Pharmacol. Ther. 1993, 59, 163-228.
18. Lin, Y.S.; Tungpradit, R.; Sinchaikul, S.; An, F.M.; Liu, D.Z.; Phutrakul, S.; Chen, S.T. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters. J. Med. Chem. 2008, 51, 7428-7441.
19. Adekola, K.; Rosen, S.T.; Shanmugam, M. Glucose transporters in cancer metabolism. Curr. Opin. Oncol. 2012, 24, 650-654.
20. Medina, R.A.; Owen, G.I. Glucose transporters: Expression, regulation and cancer. Biol. Res. 2002, 35, 9-26.
21. Macheda, M.L.; Rogers, S.; Best, J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol. 2005, 202, 654-662.
22. Calvo, M.B.; Figueroa, A.; Pulido, E.G.; Campelo, R.G.; Aparicio, L.A. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int. J. Endocrinol. 2010, doi:10.1155/2010/205357.
23. Krivopalov, V.P.; Shkurko, O.P. 1,2,3-Triazole and its derivatives. Development of methods for the formation of the triazole ring. Russ. Chem. Rev. 2005, 74, 339-379.
24. Shafran, E.A.; Bakulev, V.A.; Rozin, Y.A.; Shafran, Y.M. Condensed 1,2,3-triazoles (review). Chem. Heterocycl. Compd. 2008, 44, 1040-1069.
25. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 2001, 40, 2004-2021.
26. Huisgen, R. Centenary lecture-1, 3 dipolar cycloadditions. Proc. Chem. Soc. 1961, 6, 357-369.
27. Reddy, D.M.; Srinivas, J.; Chashoo, G.; Saxena, A.K.; Sampath Kumar, H.M. 4β-[(4-Alkyl)-1,2,3-triazol-1-yl] podophyllotoxins as anticancer compounds: Design, synthesis and biological evaluation. Eur. J. Med. Chem. 2011, 46, 1983-1991.
28. Reddy, P.B.; Paul, D.V.; Agrawal, S.K.; Saxena, A.K.; Kumar, H.M.S.; Qazi, G.N. Design, synthesis, and biological testing of 4β-[(4-substituted) -1,2,3-triazol-1-yl]podophyllotoxin analogues as antitumor agents. Archiv. Pharm. 2008, 341, 126-131.
29. Mertz, D.; Ochs, C.J.; Zhu, Z.Y.; Lee, L.; Guntari, S.N.; Such, G.K.; Goh, T.K.; Connal, L.A.; Blencowe, A.; Qiao, G.G.; et al. ATRP-mediated continuous assembly of polymers for the preparation of nanoscale films. Chem. Commun. 2011, 47, 12601-12603.
30. Gill, H.S.; Tinianow, J.N.; Ogasawara, A.; Flores, J.E.; Vanderbilt, A.N.; Raab, H.; Scheer, J.M.; Vandlen, R.; Williams, S.P.; Marik, J. A modular platform for the rapid site-specific radiolabeling of proteins with 18F exemplified by quantitative positron emission tomography of human epidermal growth factor receptor 2. J. Med. Chem. 2009, 52, 5816-5825.
31. Roy, B.; Mukhopadhyay, B. Sulfuric acid immobilized on silica: An excellent catalyst for Fischer type glycosylation. Tetrahedron Lett. 2007, 48, 3783-3787.
32. Sureshkumar, G.; Hotha, S. Gold mediated glycosylations: Selective activation of propargyl 1,2-orthoesters in the presence of aglycones containing a propargyl moiety. Chem. Commun. 2008, 36, 4282-4284.
33. Tae, H.S.; Hines, J.; Schneekloth, A.R.; Crews, C.M. Total synthesis and biological evaluation of tyroscherin. Org. Lett. 2010, 12, 4308-4311.
34. Skouroumounis, G.K.; Massy-Westropp, R.A.; Sefton, M.A.; Williams, P.J. Synthesis of glucosides related to grape and wine aroma precursors. J. Agric. Food Chem. 1995, 43, 974-980.
35. Hansen, H.F.; Jesen, R.B.; Willumsen, A.M.; Norsko-Lauritsen, N.; Ebbesen, P.; Nielen, P.E.; Buchardt, O. New compounds related to podophyllotoxin and congeners: Synthesis, structure elucidation and biological testing. Acta Chem. Scand. 1993, 47, 1190-1200.
36. Kamal, A.; Laxman, N.; Ramesh, G. Facile and efficient one-pot synthesis of 4β-arylaminopodophyllotoxins: Synthesis of DNA topoisomerase II inhibitors (NPF and W-68). Bioorg. Med. Chem. Lett. 2000, 10, 2059-2062.
37. Miller, S.J. Cellular and physiological effects of shortchain fatty acids. Mini Rev. Med. Chem. 2004, 4, 839-845.
38. Kelly, W.K.; Marks, P.A. Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydoxamic acid. Nat. Clin. Pract. Oncol. 2005, 2, 150-157.
39. Patnaik, A.; Rowinsky, E.K.; Villalona, M.A.; Hammond, L.A.; Britten, C.D.; Siu, L.L.; Goetz, A.; Felton, S.A.; Burton, S.; Valone, F.H.; et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 2002, 8, 2142-2148.
40. Finnin, M.S.; Donigian, J.R.; Cohen, A.; Richon, V.M.; Rifkind, R.A.; Marks, P.A.; Breslow, R.; Pavletich, N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
41. Sampathkumar, S.G.; Jones, M.B.; Meledeo, M.A; Campbell, C.T.; Choi, S.S.; Hida, K.; Gomutputra, P.; Sheh, A.; Gilmartin, T.; Head, S.R.; et al. Targeting glycosylation pathways and the cell cycle: Sugar-dependent activity of butyrate-carbohydrate cancer prodrugs. Chem. Biol. 2006, 13, 1265-1275.